Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial
Overview
Paper Summary
In a single-center trial, azelastine nasal spray was associated with a significantly reduced risk of SARS-CoV-2 infection in healthy, vaccinated adults. The study found a lower incidence of infections and a longer time to infection in the azelastine group compared to the placebo group, although there are some limitations regarding sample size, generalizability, and potential unblinding due to taste. Several authors also disclosed financial ties to the manufacturer of the nasal spray.
Explain Like I'm Five
A nasal spray, azelastine, may help prevent COVID infections. In a study, fewer people using the spray got COVID compared to those using a placebo spray.
Possible Conflicts of Interest
Dr. Lehr, Dr. Selzer, Dr. Smola, and Dr. Bals reported receiving grants from Ursapharm, the manufacturer of azelastine, during the study. Dr. Meiser and Dr. Holzer are employed by Ursapharm. Dr. Mösges reported grants and personal fees from Ursapharm.
Identified Limitations
Rating Explanation
This is a well-conducted randomized controlled trial with promising results. The study design is robust, and the findings are consistent across multiple analyses. However, it's important to acknowledge the limitations of a single-center trial with a limited sample size, potential unblinding, reliance on RATs, and potential placebo effects. The identified COI raises some concern but does not invalidate the findings, thus warranting a rating of 4.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →